Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients

Transplantation

Volumn 90, Issue 3, 2010, Pages 270-278

  Shariff, Hina ^a   Tanriver, Yakup ^a   Brown, Kathryn L ^a   Meader, Lucy ^a   Greenlaw, Roseanna ^a   Mamode, Nizam ^b   Jurcevic, Stipo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibody; Heart; Presensitized; T cell; Transplantation

Indexed keywords

ALLOANTIBODY; ANTIBODY; CD154 ANTIBODY; CD70 ANTIBODY; CD8 ANTIBODY; GAMMA INTERFERON; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; BLOOD VESSEL OCCLUSION; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECRETORY CELL; SPLEEN CELL; STAINING;

ANIMALS; ANTIBODIES; ANTIGENS, CD70; ANTIGENS, CD8; CD40 LIGAND; DRUG THERAPY, COMBINATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT OCCLUSION, VASCULAR; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOANTIBODIES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; SIROLIMUS; SPLEEN; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 77955429970     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e228bd     Document Type: Article

References (25)

1. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
2. Lakkis FG, Sayegh MH. Memory T cells: A hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14: 2402.
3. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol 2007; 18: 2252.
4. Macedo C, Orkis EA, Popescu I, et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009; 9: 2057.
5. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: An overlooked barrier to tolerance. Immunol Rev 2003; 196: 147.
6. Koehn B, Gangappa S, Miller JD, et al. Patients, pathogens, and protective immunity: The relevance of virus-induced alloreactivity in transplantation. J Immunol 2006; 176: 2691.
7. Wu Z, Wang Y, Gao F, et al. Critical role of CD4 help in CD154 blockade-resistant memory CD8 T cell activation and allograft rejection in sensitized recipients. J Immunol 2008; 181: 1096.
8. Greenlaw RE, Gardner NJ, Farrar CA, et al. An antibody combination that targets activated T cells extends graft survival in sensitized recipients. Am J Transplant 2008; 8: 2272.
9. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies\A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
10. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605.
11. Nimmi M. The technique for heterotypic cardiac transplantation in mice: experience of 3000 operations by one surgeon. J. Heart and Lung Transplant 2001; 20: 1123-1128.
12. Iwakoshi NN, Markees TG, Turgeon N, et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001; 167: 6623.
13. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.
14. Wehner J, Morrell CN, Reynolds T, et al. Antibody and complement in transplant vasculopathy. Circ Res 2007; 100: 191.
15. Jurcevic S, Dunn MJ, Crisp S, et al. A new enzyme-linked immu-nosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65: 1197.
16. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
17. Deuse T, Hoyt G, Koyanagi T, et al. Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation 2008; 85: 870.
18. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6(5 Pt 1): 859.
19. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res 1997; 16: 59.
20. Howland KC, Ausubel LJ, London CA, et al. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000; 164: 4465.
21. Monk NJ, Hargreaves RE, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003; 9: 1275.
22. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009; 229: 271.
23. Feuerer M, Hill JA, MathisD, et al. Foxp3+ regulatory T cells: Differentiation, specification, subphenotypes. Nat Immunol 2009; 10:689.
24. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest 2004; 114: 1398.
25. Waldmann H, Adams E, Fairchild P, et al. Regulation and privilege in transplantation tolerance. J Clin Immunol 2008; 28: 716.